pCPA
pan-Canadian Pharmaceutical Alliance (pCPA): April 2021 Trends and Insights April 2021 Highlights: 5 products completed CADTH review 6 products initiated pCPA negotiations 4 negotiations were completed with an LOI 1 negotiation was closed without an LOI 0 file was closed without negotiation Key Take-Aways: The volume of files under consideration has remained relatively high and stable for the last 5 months (27-30), although the ratio of oncology to…
Toronto, May 4th, 2021 – MORSE Consulting is pleased to release their 2021 edition of the Canadian Reimbursement and Forecasting Timelines (CRaFT) report - a comprehensive source of reimbursement timelines and insights to inform forecasting and planning needs. MORSE has analyzed Canadian market access data from 2018 through 2020 to produce key reimbursement metrics. The report will support forecasting or planning necessary for launch in Canadian by providing critical insights on the public…
pan-Canadian Pharmaceutical Alliance (pCPA): March 2021 Trends and Insights March 2021 Highlights: 5 products completed CADTH review 3 products initiated pCPA negotiations 2 negotiations were completed with an LOI 3 negotiations were closed without an LOI 0 files were closed without negotiation Key Take-Aways: The average duration that files are under consideration reaches an annual peak of ~160 days. In addition, the number of files under consideration matches…
pan-Canadian Pharmaceutical Alliance (pCPA): February 2021 Trends and Insights February 2021 Highlights: 5 products completed CADTH review 7 products initiated pCPA negotiations 6 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation Files Under pCPA Consideration: CADTH issued 5 new recommendations in February (28 files under pCPA consideration as of Feb 28) – down from 29 in January.…
Introduction The Canadian Association for Healthcare Reimbursement (CAHR) held its virtual Western Day Conference on February 9th, 2021. Members of the MORSE team attended this conference and have prepared a brief summary of the key highlights. Disclaimer: Please note, this summary is based on our team’s interpretation of the discussion. This conference was dedicated to Steve Long, who passed away of cancer in 2019. He was a friend, mentor, and…
pan-Canadian Pharmaceutical Alliance (pCPA): January 2021 Trends and Insights January 2021 Highlights: 4 products completed CADTH review 9 products initiated pCPA negotiations 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation Files Under pCPA Consideration: CADTH issued 4 new recommendations & notifications to implement in January (29 files under pCPA consideration as of January 31) – down from…
MORSE Consulting is pleased to release our Fourth Annual pCPA Year in Review Infographic – 2020 Edition. This resource is aimed at helping market access stakeholders understand the top-line pCPA highlights from 2020. This infographic compares year-over-year metrics including: pCPA activity summary; the effect of COVID-19 on under-consideration files; average time to complete a negotiation; and files adjudicated by the pCPA by type in 2020. This infographic is an excerpt…
pan-Canadian Pharmaceutical Alliance (pCPA): December 2020 Trends and Insights December 2020 Highlights: 8 products completed CADTH review 2 products initiated pCPA negotiations 4 negotiations were completed with an LOI 1 negotiation was closed without an LOI 0 files were closed without negotiation Beginning this month and over the next few months, the pCPA is introducing a Targeted Negotiation Process (TNP) to address selected files that have been on hold…
pan-Canadian Pharmaceutical Alliance (pCPA): November 2020 Trends and Insights November 2020 Highlights: 4 products completed CADTH review 8 products initiated pCPA negotiation 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Files Under pCPA Consideration: CADTH issued 4 new recommendations & notifications to implement in November (24 files under pCPA consideration as of November 30) – down…
Introduction The Canadian Association for Healthcare Reimbursement (CAHR) held its first virtual Market Access 201 conference on November 24, 2020. Members of the MORSE team attended this conference and have prepared a brief summary of the key highlights. Disclaimer: Please note, this summary is based on our team’s interpretation of the discussion. Session 1. Keynote: Evolution of HTA in United States and the Impact on International Markets …
pan-Canadian Pharmaceutical Alliance (pCPA): October 2020 Trends and Insights October 2020 Highlights: 5 products completed CADTH review 7 products initiated pCPA negotiations 5 negotiations were completed with an LOI 0 negotiations were closed without an LOI 2 files were closed without negotiation Files Under pCPA Consideration: CADTH issued 5 new recommendations in October (22 files as of October 31). PRODUCT INDICATION SPONSOR Type REC’N* DATE Xtandi** (enzalutamide) Metastatic…
pan-Canadian Pharmaceutical Alliance (pCPA): September 2020 Trends and Insights September 2020 Highlights: 1 product completed CADTH review 0 products initiated pCPA negotiations 2 negotiations were completed with an LOI 0 negotiations were closed without an LOI 1 file was closed without negotiation Files Under pCPA Consideration: CADTH issued 1 new recommendation in September (25 files as of September 30). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Zejula (niraparib) Ovarian…
pan-Canadian Pharmaceutical Alliance (pCPA): August 2020 Trends and Insights August 2020 Highlights: 2 products completed CADTH review 2 products initiated pCPA negotiations 1 negotiation was completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Files Under pCPA Consideration: CADTH issued 2 new recommendations in August (25 files as of August 31). PRODUCT INDICATION SPONSOR HTA REC’N* DATE Soliris (eculizumab) Neuromyelitis…
Toronto, September 9, 2020 – MORSE Consulting is pleased to announce that Sal Cimino has joined our team as Senior Consultant, Private Drug Plans. The private payer market is playing an increasingly important role in ensuring a product’s reimbursement success in Canada. With the introduction of new specialty biologics and gene therapies, private payers are turning to new cost containment strategies that strongly resemble the public payer market. Private payers…
pan-Canadian Pharmaceutical Alliance (pCPA): July 2020 Trends and Insights July 2020 Highlights: 6 products completed CADTH review 6 products initiated pCPA negotiations 7 negotiations were completed with an LOI 0 negotiations were closed without an LOI 0 files were closed without negotiation Trends are beginning to emerge regarding impact of COVID19 on pCPA negotiations with 3 months of experience to consider. In general, negotiations are taking longer to start…
Contact Us
MORSE Consulting Inc.
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. |
Site by Directica Media
pCPA - Info and details on - Page 3 of 9 - MORSE Consulting Inc.
